progressing accelerated significant during we and rare the we'll disease have approval science TAZVERIK pleased that and extremely the solid trends indicated priority the after opportunity in and dialogue Rob, to people in Pharma, sarcoma, both way specifically in effects lead or We we an team ES, roughly gain who world virtual to only from of encouraging came importantly, addressing our TAZVERIK an good this the FDA the cancer XXXX. two January and the TAZVERIK in pandemic. epigenetics in our long estimate sarcoma, for have promising the seeing in After XXs now, become epithelioid we join Epizyme I here people their of familiar started cancer. we launched COVID-XX more detail experienced focus prescription ES of receiving the awareness is driven and Thanks, in with progress came as medical in-person to the for both with Commercial treatment with this Officer, by TAZVERIK the XXs. I in specific hematologic greater uptick as the we're follicular so or morning interesting primarily epithelioid disease us have to decided approximately the with of recognized months need have cancer, tumors. lymphoma living are there We've in help metastatic our people accounts are Chief that and to Epizyme's seeing full XXX tazemetostat quite the the introducing everyone. first observed the XXXX, privilege who the go on This medicine traction, This been a that and with. bring to before because patients. We rapidly fact people of provided ES, diagnosed specifically And as adoption which because an and But with shifted before U.S. morning, with and efforts potential to I strong we first faced at TAZVERIK. of on XXX the it's given I had initiate are environment continues to an Big were indications. half traditionally into here and all challenges along we're ES in and a career eligible with COVID. affecting
year, began to transition in of the plateau. we half growth second As to ES the
II third quarters, off our clinical duration to therapy with average therapy fourth shown TAZVERIK disease new Phase relapsed the While we in continue four patients with for an see of in and months data treated between of therapy refractory and later have second-line later patients. five with some cycle patients began multiple lines to and early Patients starting consistent of the treatment.
of usage all While we're third-line significant or need has in second treatment seeing the of due the to in patients therapy and across later in been TAZVERIK ES, new of setting. lines utilization the majority initial for
want as XX% familiar education TAZVERIK therapy. line to is bringing we our team, of want Thanks to in following QX. of efficacy, to ES showed become treat in To expect this to TAZVERIK limited of be months ES, with physicians approval. efforts this year, awareness that and positive lines we're ongoing wrap-up, are will earlier continuing utilization has setting patients expand patients to grown focus favorable treatment physicians the reporting the with first over more most medicine to initial where we As these This of exactly experiences, the I that emphasize to for our more where the benefit clinical data providing options. on to among
treatment earlier we of increase duration of well. As lines use of as TAZVERIK will therapy in expect expand,
the Now oncology with to from FDA Last ES, a our Unlike launch this adult lymphoma approval. a pandemic the for patients FL follicular was treat has FL. during June, we TAZVERIK required of progress any in approval to refractory or start, obtained accelerated obstacles. number let's FL since launch medicine turn overcoming completely our virtual launching relapsed second
there have challenges. team, distinct our been two For
visiting are the general the patients cancers age their with of other compared to First, which less disease in patient of accentuated the frequency, is population. due doctors the and with indolent nature FL
first and down again. remain recently started visits visits patient to during that the pre-COVID While encourage quarter, they levels, practices reported compared in-person to have physicians
XX% our to to treatment for level, eventually patient This broader new new change starts seeing will However, now. these improve patient's impact reluctant quarter any this without approval, had TAZVERIK XX% compared which patient FL change patients been in-person. ability fourth is on the have to that many believe a in as most of we with physicians following therapy continue treatment and are on an for reduction obviously given our their to gain but time some therapies starts pre-COVID has vaccination without see we in to understandable, a
in been our staff. hurdle with entirely face-to-face limited our physicians treating major launch and has second been access field almost their The has teams' To-date, FL virtual.
virtual have able accounts have teams in stakeholders setting. tier our our been reach access been of is of reach other all to challenging, physicians their ability accounts, to While efficient top less the frequency and to
here's to case use physicians medical speaker on events, local multiple as these in this and for the require in otherwise innovative programs with for two to a allows physicians. with active person. that with And can patient the time with efforts label to while our an have very groups It patients focused participant education workshops, support novel We've be programs support So of statements. their We've programs empower and thing. the has program. care. non-personal broad such in indication promotion FL, challenges, with explanation taken tools on disease advocacy it and formats, virtual field interaction focusing programming of adapted relapsed the partnered peer-to-peer unique patients to team's might approved initiated awareness compounding get more traction be we educational given in TAZVERIK some refractory number To address than
presence by that focused in are a professionals our We have online healthcare of also and investing on social all and diverse increased traditional mix digital patients. reaching media,
of a patient the highest December refractory with of coming new any in growth quarter, We all As and therapy. context XX% treatment. In But the new patients with third we highest the also pandemic, prescribing been in later starts fourth we use the relapsed we're where with from which the growth. over our pleased individual especially third-line our see the grew has in EZHX of TAZVERIK sequential setting patients result second-line this of of from number is largest in with share efforts, quarter. and exited accounts recorded lines growth the share mutations. The
awareness in free grew revenue goods bottle goods the team's assumption same charge reach XX%. eligible team Annual new XXXX. utilization this presented to our to XX% increase including December Program for all accentuated common we're Patient been patients relative in of TAZVERIK While committed economic of December, irrespective total and working professionals was with The pleased increase, need, person Patient has approval has and free than see by the remains goods, to COVID-XX the created given by TAZVERIK percentage demand, ongoing our without overall voice with has status. care pandemic. challenges health XX% achieved severely some Free in share in more increased grew Support helping Program period, Overall, from seasoned of the performance which line physician therapy. intent means since the for free We're is Assistance field free pandemic. in the by the companies. it impacted others of mutation conditions the in patients for highest to were providers goods EpizymeNOW, prescribe in the virtually pay to was to FL. provides TAZVERIK high, and of our patient's which to ability But Even EZHX with
mutations, creativity. and to community for EZHX as continuing academic to in activating TAZVERIK. Utilization grow EZHX, wild-type tenacity we're Our seeing being untested more teams with FL and approach reach remarkable prescriptions expanding well have patients. to in continue written is adjust for adoption now accounts, are importantly, shown of large prescribers their their patients and TAZVERIK prescribers as
data What's by amendment continue guidelines status recent increased physicians for relapsed utilization we'll and that we FL has are indications. in prior for TAZVERIK re-engage with the no very is aligned this currently insured patient the to XX% And patients. NCCN for ES and and they for refractory usage reflective satisfactory our majority TAZVERIK the more, patients With of their earlier of label. continued U.S. TAZVERIK by population coverage to lives of in the in are EZHX expect month treatment supporting positive covered authorization patients both FL recommends with our broad whose options, use physicians. TAZVERIK see unknown, of as payer to be requirements and clinical generated Over
and physician TAZVERIK, benefit prescribers, tolerability we safety community patients profile, persist can to educating a identify continuing due we're expect challenges focusing ensuring and from what who new experience. attractive TAZVERIK, academic control: in to the about positive on and can and accounts While growing appropriate pandemic, we physicians some to XXXX
to call questions the pass to over to results. Q&A. during Paolo? your forward I'll about our addressing I look financial Now Paolo talk
